IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Clinical trial NCT05073250 · UNKNOWN

Trial details

NCT number: NCT05073250
Sponsor: Chinese PLA General Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Inert Non Hodgkin's Lymphoma

Start date: 2021-12-31
Primary completion: 2023-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.